Category:

Release – Kelly Announces Third-Quarter 2024 Conference Call

Posted on by dburczyk@noblecapitalmarkets.com

Research News and Market Data on KELYA

TROY, Mich., Oct. 24, 2024 (GLOBE NEWSWIRE) — Kelly, a leading global specialty talent solutions provider, will release its third-quarter earnings before the market opens on Thursday, November 7, 2024. In conjunction with its third-quarter earnings release, Kelly will publish a financial presentation on the Investor Relations page of its public website and will host a conference call at 9 a.m. ET.

The call may be accessed in one of the following ways:

Via the internet:
kellyservices.com

Via the telephone:
(877) 692-8955 (toll free) or (234) 720-6979 (caller paid)
Enter access code 5728672
After the prompt, please enter “#”

A recording of the conference call will be available after 1:30 p.m. ET on November 7, 2024, at (866) 207-1041 (toll-free) and (402) 970-0847 (caller-paid). The access code is 9480328#. The recording will also be available at kellyservices.com during this period.

About Kelly

Kelly Services, Inc. (Nasdaq: KELYA, KELYB) helps companies recruit and manage skilled workers and helps job seekers find great work. Since inventing the staffing industry in 1946, we have become experts in the many industries and local and global markets we serve. With a network of suppliers and partners around the world, we connect more than 500,000 people with work every year. Our suite of outsourcing and consulting services ensures companies have the people they need, when and where they are needed most. Headquartered in Troy, Michigan, we empower businesses and individuals to access limitless opportunities in industries such as science, engineering, technology, education, manufacturing, retail, finance, and energy. Revenue in 2023 was $4.8 billion. Learn more at kellyservices.com.

KLYA-FIN

Analyst & Media Contact:
Scott Thomas
(248) 251-7264
scott.thomas@kellyservices.com

Release – The ODP Corporation to Announce Third Quarter 2024 Results Wednesday, November 6, 2024

Posted on by dburczyk@noblecapitalmarkets.com

Research News and Market Data on ODP

BOCA RATON, Fla.–(BUSINESS WIRE)–Oct. 23, 2024– The ODP Corporation (NASDAQ:ODP) (“ODP,” or the “Company”), a leading provider of products, services, and technology solutions to businesses and consumers, will announce third quarter 2024 financial results before the market open on Wednesday, November 6th, 2024. The ODP Corporation will webcast a call with financial analysts and investors that day at 9:00 am Eastern Time which will be accessible to the media and the general public.

To listen to the conference call via webcast, please visit The ODP Corporation’s Investor Relations website at investor.theodpcorp.com. A replay of the webcast will be available approximately two hours following the event. A copy of the earnings press release, supplemental financial disclosures and presentation will also be available on the website.

About The ODP Corporation
The ODP Corporation (NASDAQ:ODP) is a leading provider of products and services through an integrated business-to-business (B2B) distribution platform and omnichannel presence, which includes world-class supply chain and distribution operations, dedicated sales professionals, online presence and a network of Office Depot and OfficeMax retail stores. Through its operating companies Office Depot, LLC; ODP Business Solutions, LLC; and Veyer, LLC, The ODP Corporation empowers every business, professional, and consumer to achieve more every day. For more information, visit theodpcorp.com.

ODP and ODP Business Solutions are trademarks of ODP Business Solutions, LLC. Office Depot is a trademark of The Office Club, LLC. OfficeMax is a trademark of OMX, Inc. Veyer is a trademark of Veyer, LLC. Grand&Toy is a trademark of Grand & Toy, LLC in Canada. Any other product or company names mentioned herein are the trademarks of their respective owners.

Tim Perrott
Investor Relations
561-438-4629
Tim.Perrott@theodpcorp.com

Source: The ODP Corporation

Release – GoHealth to Announce Third Quarter 2024 Results on November 7, 2024

Posted on by aweinsoff@channelchek.com

Research News and Market Data on GOCO

Oct 24, 2024 at 8:00 AM EDT

CHICAGO, Oct. 24, 2024 (GLOBE NEWSWIRE) — GoHealth, Inc. (GoHealth) (NASDAQ: GOCO), a leading health insurance marketplace and Medicare-focused digital health company, announced that the company will release its third quarter 2024 financial results on the morning of November 7, 2024.

Chief Executive Officer, Vijay Kotte, and Chief Financial Officer, Brendan Shanahan, will host a conference call and live audio webcast on the day of the release at 8:00 a.m. (ET) to discuss the results.

A live audio webcast of the conference call will be available via GoHealth’s Investor Relations website, https://investors.gohealth.com/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call.

About GoHealth, Inc.

GoHealth is a leading health insurance marketplace and Medicare-focused digital health company whose purpose is to compassionately ensure consumers’ peace of mind when making healthcare decisions so they can focus on living life. For many of these consumers, enrolling in a health insurance plan is confusing and difficult, and seemingly small differences between health plans may lead to significant out-of-pocket costs or lack of access to critical providers and medicines. GoHealth’s proprietary technology platform leverages modern machine-learning algorithms, powered by over two decades of insurance purchasing behavior, to reimagine the process of matching a health plan to a consumer’s specific needs. Its unbiased, technology-driven marketplace coupled with highly skilled licensed agents has facilitated the enrollment of millions of consumers in Medicare plans since GoHealth’s inception. For more information, visit https://www.gohealth.com.

Investor Relations
John Shave
jshave@gohealth.com

Media Relations
Pressinquiries@gohealth.com

Release – NN, Inc. to Reschedule Third Quarter 2024 Earnings Conference Call for Thursday, October 31, 2024

Posted on by dburczyk@noblecapitalmarkets.com

Research News and Market Data on NNBR

CHARLOTTE, N.C., Oct. 23, 2024 (GLOBE NEWSWIRE) — NN, Inc. (NASDAQ: NNBR), a global diversified industrial company that engineers and manufactures high-precision components and assemblies, announced today that it has rescheduled the release of its third quarter 2024 financial results for the period ended September 30th, 2024.

The Company will now publish its third quarter earnings one day earlier than its previously scheduled release, after the close of the market on Wednesday, October 30th, 2024. The Company will hold a related conference call on Thursday, October 31st, 2024, at 9:00 a.m. E.T. Participants on the call are asked to register five to ten minutes prior to the scheduled start time by dialing 1-877-255-4315 and from outside the U.S. at 1-412-317-6579.

The conference call will be webcast simultaneously and in its entirety through the NN, Inc. Investor Relations website. Shareholders, media representatives and others may participate in the webcast by registering through the Investor Relations section on the company’s website at https://investors.nninc.com/.

For those who are unavailable to listen to the live call, a replay will be available shortly after the call on NN’s website through October 31st, 2025.

About NN, Inc.
NN, Inc., a global diversified industrial company, combines advanced engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision components and assemblies for a variety of markets on a global basis. Headquartered in Charlotte, North Carolina, NN has facilities in North America, Europe, South America, and Asia. For more information about the company and its products, please visit www.nninc.com.

Investor Relations Contacts:
Joe Caminiti or Stephen Poe
NNBR@alpha-ir.com
312-445-2870

Source: NN, Inc.

Release – Tonix Pharmaceuticals Announces Oral Presentation at the World Vaccine Congress Europe 2024

Posted on by aweinsoff@channelchek.com

Research News and Market Data on TNXP

October 24, 2024 8:00am EDT

CHATHAM, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Zeil Rosenberg, M.D., M.P.H., Executive Vice President, Medical, Tonix Pharmaceuticals, will deliver an oral presentation at the World Vaccine Congress Europe, which will be held in Barcelona, Spain, October 28-31, 2024. A copy of the Company’s presentation will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference. Additional meeting information can be found on the World Vaccine Congress Europe website here.

Presentation Details
  
Presenter:Zeil Rosenberg, M.D., M.P.H.
Title:A Novel, Single-dose, Live, Attenuated, Minimally Replicating Mpox Vaccine
Location:Fira de Barcelona – Montjuïc – Hall 2
Date:Wednesday, October 30, 2024
Time:2:10 p.m. GMT
 

Tonix Pharmaceuticals Holding Corp.*

Tonix is a fully integrated biopharmaceutical company focused on transforming therapies for pain management and modernizing solutions for public health challenges. Tonix’s development portfolio is focused on central nervous system (CNS) disorders, and its priority is to progress TNX-102 SL, a product candidate for which an NDA was submitted based on two statistically significant Phase 3 studies for the management of fibromyalgia. The FDA has granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic in Phase 2 development designed to treat cocaine intoxication that has FDA Breakthrough Therapy designation and its development is supported by a grant from the U.S. National Institute of Drug Abuse and Addiction. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease, including TNX-2900 for Prader-Willi syndrome, and infectious disease, including a vaccine for mpox, TNX-801. Tonix recently announced a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years to develop TNX-4200, small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, MD. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.

* Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contact

Jessica Morris
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 904-8182

Peter Vozzo
ICR Healthcare
peter.vozzo@westwicke.com
(443) 213-0505

Media Contact

Ray Jordan
Putnam Insights
ray@putnaminsights.com
(949) 245-5432

Primary Logo

Source: Tonix Pharmaceuticals Holding Corp.

Released October 24, 2024

Release – Beasley Broadcast Group, Inc. Appoints Lauren Burrows Coleman as Chief Financial Officer

Posted on by aweinsoff@channelchek.com

Research News and Market Data on BBGI

Marie Tedesco to Retire as CFO Following Three Decades of Service

October 24, 2024 07:00 ET

    NAPLES, Fla., Oct. 24, 2024 (GLOBE NEWSWIRE) — Beasley Broadcast Group, Inc. (Nasdaq: BBGI), a multi-platform media company, today announced the appointment of Lauren Burrows Coleman as Chief Financial Officer, effective Friday, November 1, 2024. Longtime CFO Marie Tedesco will retire from Beasley after 33 years of dedicated service to the company.

    Before joining Beasley, Ms. Burrows Coleman served as Global Head of Strategic Corporate and Commercial Finance at Wayfair (NYSE: W), where she led a global team of 50 across Financial Planning & Analysis, Commercial Finance, Capital Markets, Corporate Development, and Global Tax functions.

    Ms. Burrows Coleman’s impressive career also includes leadership positions at WindSail Capital Group and Wind Point Partners, both private equity firms, as well as GE Capital, where she managed equity and debt investments across various industries. She began her career as an investment banker in the Communications & Media group at Lehman Brothers.

    “We are absolutely thrilled to welcome Lauren into the Beasley family,” said Caroline Beasley, Chief Executive Officer of Beasley Broadcast Group, Inc. “Her extensive and diverse experience, combined with her leadership skills, are exactly what we need to drive the company forward as we evolve into the future.”

    Ms. Burrows Coleman holds an MBA from Harvard Business School and an A.B. cum laude from Dartmouth College.

    She will succeed Marie Tedesco, who is retiring on November 1st after more than three decades with the organization.

    “Marie has been an integral part of our success and her contributions have shaped the organization into what it is today,” said Caroline Beasley. “It has been a privilege to work alongside her, and we are deeply grateful for her unwavering commitment, hard work, and leadership. We will greatly miss Marie’s wisdom and guidance, and we wish her nothing but the very best!”

    About Beasley Broadcast Group:
    Beasley Broadcast Group, Inc. (NASDAQ: BBGI) is a multi-platform media company whose primary business is operating radio stations throughout the United States. The Company offers local and national advertisers integrated marketing solutions across audio, digital and event platforms. The Company owns and operates stations in the following markets: Atlanta, GA, Augusta, GA, Boston, MA, Charlotte, NC, Detroit, MI, Fayetteville, NC, Fort Myers-Naples, FL, Las Vegas, NV, Middlesex, NJ, Monmouth, NJ, Morristown, NJ, Philadelphia, PA, and Tampa-Saint Petersburg, FL. Approximately 20 million consumers listen to the Company’s radio stations weekly over-the-air, online and on smartphones and tablets, and millions regularly engage with the Company’s brands and personalities through digital platforms such as Facebook, Twitter, text, apps and email. For more information, please visit www.bbgi.com.

    Contact

    Joseph Jaffoni, Jennifer Neuman JCIR
    (212) 835-8500
    bbgi@jcir.com

    Heidi Raphael, BBGI
    (239) 263-5000

    Travelzoo (TZOO) – Acceleration In Growth Expected In 2025

    Posted on by cpereira@noblefcm.com


    Thursday, October 24, 2024

    Travelzoo® provides its 30 million members with exclusive offers and one-of-a-kind experiences personally reviewed by our deal experts around the globe. We have our finger on the pulse of outstanding travel, entertainment, and lifestyle experiences. We work in partnership with more than 5,000 top travel suppliers—our long-standing relationships give Travelzoo members access to irresistible deals.

    Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

    Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

    Refer to the full report for the price target, fundamental analysis, and rating.

    Steady as she goes. Third quarter results were in line with our estimates, with revenue of $20.1 million (down 2.4% year over year), versus our estimate of $20.9 million. Adj. EBITDA was $4.6 million (up 19.3% year over year), better than our estimate of $3.8 million by almost 21% due to lower than expected sales & marketing expenses.

    Swing toward revenue growth. Advertising revenue was down slightly to $19.7 million from $20.0 million in Q2, with membership revenue up from $1.2 million in Q2 to $1.4 million in Q3. The membership revenue increase reflected improved subscriptions with Jack’s Flight Club, which was expanded into Canada. 


    Get the Full Report

    Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

    This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

    *Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

    The ODP Corporation (ODP) – A Varis Sale

    Posted on by cpereira@noblefcm.com


    Thursday, October 24, 2024

    Office Depot, Inc., together with its subsidiaries, supplies a range of office products and services. It offers merchandise, such as general office supplies, computer supplies, business machines and related supplies, and office furniture through its chain of office supply stores under the Office Depot, Foray, Ativa, Break Escapes, Worklife, and Christopher Lowell brand names. The company also provides graphic design, printing, reproduction, mailing, shipping, and other services through design, print, and ship centers. It has operations throughout North America, Europe, Asia, and Central America. The company also sells its products and services through direct mail catalogs, contract sales force, Internet sites, and retail stores, through a mix of company-owned operations, joint ventures, licensing and franchise agreements, alliances, and other arrangements. As of December 31, 2008, Office Depot operated 1,267 North American retail division office supply stores and 162 international division retail stores, as well as participated under licensing and merchandise arrangements in 98 stores. The company was founded in 1986 and is based in Boca Raton, Florida.

    Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

    Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

    Refer to the full report for the price target, fundamental analysis, and rating.

    A Sale. The ODP Corporation reported that on October 18, 2024, the Company sold its Varis Division to an affiliate of Arising Ventures. The Company did not release the terms of the agreement. We expect to see additional detail on the Company’s third quarter earnings call.

    Details. ODP is retaining a minority interest of 19.9% after the sale. Under the terms of the agreement, the Company will fund up to $4 million of expenses that Varis may incur following the transaction date until December 31, 2025, and has no further obligations to contribute capital to Varis. The terms of the sale did not result in a materially different impact on the Company’s financial statements than previously estimated.


    Get the Full Report

    Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

    This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

    *Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

    FreightCar America (RAIL) – Raising Price Target Based on Higher Revenue and Margin Growth Expectations

    Posted on by cpereira@noblefcm.com


    Thursday, October 24, 2024

    Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

    Refer to the full report for the price target, fundamental analysis, and rating.

    Pure play manufacturer. FreightCar America, Inc. is a diversified manufacturer of railroad cars and rail car components. The company designs and manufactures a broad variety of railroad car types for the transportation of bulk commodities and containerized freight products primarily in North America. The company reported strong second-quarter financial results and appears poised for greater scale and margin expansion as it increases its market share and expands its product suite.

    On the path to greater profitability. While the company has broadened and diversified its product portfolio, we expect further growth into new areas such as producing tank cars which is expected to support margin expansion. Growth in the conversion and rebody business, along with increased parts sales, could enhance gross margins and reduce the company’s top-line sensitivity to the cyclicality associated with new railroad car orders. Additionally, we think FreightCar America will continue to improve its cost profile through productivity and efficiency gains.


    Get the Full Report

    Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

    This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

    *Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

    Weekly Jobless Claims Decline to Lowest in Nearly a Month

    Posted on by slightbourne@noblecapitalmarkets.com
    Key Points:
    – Weekly jobless claims dropped to 227,000, the lowest in nearly a month, beating economist expectations.
    – Continuing claims rose slightly to 1.89 million, the highest since November 2021.
    – The labor market remains stable, with layoffs staying limited despite economic uncertainties and recent weather disruptions.

    Weekly jobless claims in the U.S. unexpectedly fell last week, indicating a resilient labor market despite economic uncertainties and recent disruptions. The latest data from the Department of Labor showed that 227,000 initial jobless claims were filed in the week ending October 19, a notable decrease from 241,000 the week prior. This was below the 242,000 claims economists had expected, according to Bloomberg data.

    This reversal marks a break in the upward trend that began in September, which had pushed jobless claims to their highest levels in over a year. While jobless claims provide an indication of layoffs and labor market churn, the continued decline shows that turnover remains low, and layoffs are not spiking despite broader concerns about the economy.

    In addition to initial claims, continuing claims, which measure the number of people still receiving unemployment benefits, rose slightly to 1.89 million for the week ending October 12. This is up from 1.86 million the previous week and marks the highest level since November 2021.

    Economists believe the recent drop in jobless claims reflects a recovery from weather-related disruptions, particularly hurricanes in the southern U.S. “Claims in some states affected by Hurricane Helene retreated from recent highs, though claims in Florida rose, likely due to Hurricane Milton,” noted Oxford Economics senior economist Nancy Vanden Houten. With jobless claims now back to pre-hurricane levels, the data suggests the labor market remains steady, with few layoffs across the board.

    Experts have pointed out that, despite fluctuations in the data, the job market continues to show resilience in the face of ongoing challenges. The Federal Reserve’s October Beige Book report, which surveys firms across the central bank’s 12 districts, revealed that worker turnover is low and layoffs have remained limited. This finding mirrors other reports that show hiring and quit rates have fallen this year but layoffs have not reached alarming levels.

    In fact, many companies are focusing more on replacing workers than expanding their workforce, demonstrating cautious optimism. “The job market continues to shrug off prevailing worries and uncertainties,” noted Oren Klachkin, economist at Nationwide Financial Markets. While employers may be cautious about future economic conditions, they remain hesitant to let go of workers in large numbers.

    The steady drop in jobless claims aligns with other indicators that suggest the labor market is cooling but remains robust. Unemployment rates have stayed low, and next week’s data on job openings, quits, and the hiring rate will provide more insight into the state of the labor market.

    This labor data comes ahead of a key Federal Reserve meeting in November. Traders are currently pricing in a 95% chance of the Federal Reserve cutting interest rates by 25 basis points. The outcome of this meeting could heavily depend on next week’s data releases and the October jobs report, which is expected to show the U.S. economy adding 135,000 jobs in October, down from 254,000 in September. The unemployment rate is expected to remain steady.

    Overall, while labor market growth may be slowing, the low turnover and limited layoffs provide a solid foundation as the U.S. economy navigates uncertainties.

    Release – CVG Announces Third Quarter 2024 Earnings Call

    Posted on by dburczyk@noblecapitalmarkets.com

    Research News and Market Data on CVGI

    NEW ALBANY, Ohio, Oct. 22, 2024 (GLOBE NEWSWIRE) — CVG (NASDAQ: CVGI) will hold its quarterly conference call on Tuesday, November 5, 2024, at 8:30 a.m. ET, to discuss third quarter 2024 financial results. CVG will issue a press release and presentation prior to the conference call.

    Toll-free participants dial (800) 549-8228 using conference code 04909. International participants dial (289) 819-1520 using conference code 04909. This call is being webcast and can be accessed through the “Investors” section of CVG’s website at ir.cvgrp.com where it will be archived for one year.

    A telephonic replay of the conference call will be available until November 19, 2024. To access the replay, toll-free callers can dial (+1) 888 660 6264 using access code 04909#, and toll callers in North America and other locations can dial (+1) 289 819 1325.

    About CVG

    At CVG, we deliver real solutions to complex design, engineering and manufacturing problems while creating positive change for our customers, industries, and communities we serve. Information about the Company and its products is available on the internet at www.cvgrp.com.

    Investor Relations Contact:
    Ross Collins or Stephen Poe
    Alpha IR Group
    CVGI@alpha-ir.com

    Source: Commercial Vehicle Group, Inc.

    Release – Cadrenal Therapeutics Joins Corporate Council Of Anticoagulation Forum

    Posted on by aweinsoff@channelchek.com

    Research News and Market Data on CVKD

    Participation Reinforces Cadrenal’s Commitment to Innovation, Education and Improved Patient Outcomes with Anticoagulation Therapy

    PONTE VEDRA, Fla., Oct. 23, 2024 — Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to improve anticoagulation for patients with implanted cardiac devices or rare cardiovascular conditions, today announced its membership in the Corporate Council of the Anticoagulation Forum (AC Forum).

    Cadrenal Therapeutics, Inc. is a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug designation. (PRNewsfoto/Cadrenal Therapeutics, Inc.)


    The AC Forum is the largest professional organization of anticoagulation specialists, committed to advancing the quality and safety of chronic anticoagulation care globally. Through participation in the Corporate Council, Cadrenal Therapeutics will collaborate with the AC Forum as it works to identify and address unmet clinical needs, share cutting-edge research, and promote advocacy and educational initiatives for the organization’s 15,000 healthcare professional members aimed at improving outcomes for patients on anticoagulants.

    “Our membership in the AC Forum’s Corporate Council reflects our shared commitment to transforming anticoagulation care,” said Quang X. Pham, Chief Executive Officer of Cadrenal Therapeutics. “We look forward to partnering with the AC Forum and contributing to programs that advance safer, more effective care and inform about ongoing research and anticoagulation best practice guidelines.”

    Darren Triller, PharmD, Director of Strategic Initiatives at the Anticoagulation Forum, welcomed Cadrenal Therapeutics to the Corporate Council, saying: “We are excited to have Cadrenal Therapeutics join us in our mission to improve the quality of care for patients receiving antithrombotic therapies. We look forward to a productive partnership that will help us address the challenges in the anticoagulation landscape together.”

    About Cadrenal Therapeutics, Inc.

    Cadrenal Therapeutics is a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to offer safer, superior chronic anticoagulation for patients with implanted cardiac devices or rare cardiovascular conditions. Tecarfarin is anticipated to result in fewer adverse events such as strokes, heart attacks, bleeds and deaths than warfarin, the most commonly used anticoagulant for these patients despite its prevalent side effects, drug-to-drug interactions and frequent dosing changes. Tecarfarin received an orphan drug designation for advanced heart failure patients with implanted left ventricular assist devices (LVADs) as well as both orphan drug and fast-track status for end-stage kidney disease patients with atrial fibrillation. Cadrenal is planning pivotal clinical trials and pursuing clinical and commercial partnerships. The company’s plans also include studying tecarfarin in patients with mechanical heart valves experiencing anticoagulation difficulties. Visit www.cadrenal.com to learn more.

    About the Anticoagulation Forum

    The Anticoagulation Forum has led advancements in thrombosis-related care for over three decades. With more than 15,000 members across 3,000 healthcare institutions, the AC Forum is dedicated to enhancing the safety and quality of care for over 1 million patients annually. Through education, thought leadership, and partnerships with industry leaders, the AC Forum shapes the future of anticoagulation management to ensure the best outcomes for patients.

    For more information, please contact:
    Cadrenal Therapeutics:
    Matthew Szot, CFO
    858-337-0766
    press@cadrenal.com

    Investors:
    Lytham Partners, LLC
    Robert Blum, Managing Partner
    602-889-9700
    CVKD@lythampartners.com

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cadrenal-therapeutics-joins-corporate-council-of-anticoagulation-forum-302283944.html

    SOURCE Cadrenal Therapeutics, Inc.

    Release – Conduent to Report Third-Quarter 2024 Financial Results on Nov. 6, 2024

    Posted on by aweinsoff@channelchek.com

    Research News and Market Data on CNDT

    October 23, 2024

    Earnings/Financial

    FLORHAM PARK, N.J. — Conduent Incorporated (Nasdaq: CNDT), a global technology-led business solutions and services company, plans to report its third-quarter 2024 financial results on Wednesday, November 6 before market open. Management will present the results during a conference call and webcast at 9:00 a.m. ET.

    The call will be available by live audio cast along with the news release and online presentation slides at https://investor.conduent.com.

    The conference call will also be available by calling 877-407-4019 toll free. If requested, the conference ID 13748951.

    The international dial-in is +1 201-689-8337. The international conference ID is also 13748951.

    A recording of the conference call will be available by calling 877-660-6853 three hours after the conference call concludes. The access ID for the recording is 13748951.

    The call recording will be available until November 20, 2024.

    We look forward to your participation.

    About Conduent

    Conduent delivers digital business solutions and services spanning the commercial, government and transportation spectrum – creating valuable outcomes for its clients and the millions of people who count on them. The Company leverages cloud computing, artificial intelligence, machine learning, automation and advanced analytics to deliver mission-critical solutions. Through a dedicated global team of approximately 55,000 associates, process expertise and advanced technologies, Conduent’s solutions and services digitally transform its clients’ operations to enhance customer experiences, improve performance, increase efficiencies and reduce costs. Conduent adds momentum to its clients’ missions in many ways including disbursing approximately $100 billion in government payments annually, enabling 2.3 billion customer service interactions annually, empowering millions of employees through HR services every year and processing nearly 13 million tolling transactions every day. Learn more at www.conduent.com.

    Note: To receive RSS news feeds, visit www.news.conduent.com. For open commentary, industry perspectives and views, visit http://twitter.com/Conduent, http://www.linkedin.com/company/conduent or http://www.facebook.com/Conduent.

    Trademarks

    Conduent is a trademark of Conduent Incorporated in the United States and/or other countries. Other names may be trademarks of their respective owners.

    Media Contacts

    Sean Collins

    Conduent

    Sean.Collins2@conduent.com

    +1-310-497-9205

    Giles Goodburn

    Conduent

    ir@conduent.com

    +1-203-216-3546